Your Browser Is No Longer Supported. Please upgrade your browser from Internet Explorer 10 to Internet Explorer 11 or higher
SHM joined a multi-stakeholder letter urging Congress to expand access to buprenorphine. The letter urged Congress to include legislation to address the opioid epidemic in the upcoming COVID
SHM joined a multi-stakeholder letter urging the Acting Secretary of Health and Human Services (HHS) to finalize guidelines that would expand access to buprenorphine.
SHM responds to the House Energy and Commerce Republicans' request for information regarding opioid and substance use disorder treatment. This letter focuses specifically on the need to deregulate
The Mainstreaming Addiction Treatment Act (S. 2074) is the companion bill to H.R. 2482. This bill will increase access to buprenorphine, a lifesaving addiction treatment, by eliminating the "X
SHM sent a support letter to Reps. Blumenauer and Mullin for their legislation, the Overdose Prevention and Patient Safety Act.
SHM urges Congress to take action to address the opioid crisis facing the United States.
SHM submitted comments regarding the pain management questions in the HCAHPS survey to Medicare in the Outpatient Prospective Payment System (OPPS) proposed rule.
Along with other organizations, SHM signs onto a letter to CMS supporting antibiotic stewardship requirements for long term care facilities (LTCFs) in order to participate in Medicare programs.
We write to you as leading participants in the prescription drug supply chain – i.e., manufacturers, distributors, payers, physicians, pharmacies, testing laboratories, treatment providers – as
SHM supports the reintroduction of the Mainstreaming Addiction Treatment Act. This legislation will eliminate the X-Waiver prescribing requirement for buprenorphine, a lifesaving medication used